AAV10-U7-CTR

AAV10-U7-CTR is an experimental gene therapy that utilizes an adeno-associated virus serotype rh10 (AAV10) vector to deliver engineered U7 small nuclear RNA (snRNA) sequences. The U7 snRNA is modified to induce exon skipping in target pre-mRNAs, a strategy particularly useful for diseases caused by splicing defects. In the context of amyotrophic lateral sclerosis (ALS) linked to superoxide dismutase 1 (SOD1), similar constructs have been used to mediate exon skipping of mutant SOD1 pre-mRNA, leading to its degradation via nonsense-mediated decay and resulting in reduced levels of toxic protein. This approach has shown therapeutic effects in animal models, including prolonged survival and improved neuromuscular function[1][2]. The "CTR" suffix likely denotes a control or reference construct used in research settings.